Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells

BACKGROUND: BRAF inhibitors are effective anticancer agents in BRAF-mutated melanomas. By contrast, evidences about sensitivity of thyroid carcinomas to BRAF inhibition are conflicting and it has been proposed that BRAF V600E thyroid carcinoma cells are less sensitive to BRAF inhibitors due to activ...

Descripción completa

Detalles Bibliográficos
Autores principales: Notarangelo, Tiziana, Sisinni, Lorenza, Condelli, Valentina, Landriscina, Matteo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628448/
https://www.ncbi.nlm.nih.gov/pubmed/29033690
http://dx.doi.org/10.1186/s12935-017-0457-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628448/
https://www.ncbi.nlm.nih.gov/pubmed/29033690
http://dx.doi.org/10.1186/s12935-017-0457-z

Ejemplares similares